TY - JOUR
T1 - Differences in Liver Parenchyma are Measurable with CT Radiomics at Initial Colon Resection in Patients that Develop Hepatic Metastases from Stage II/III Colon Cancer
AU - Creasy, John M.
AU - Cunanan, Kristen M.
AU - Chakraborty, Jayasree
AU - McAuliffe, John C.
AU - Chou, Joanne
AU - Gonen, Mithat
AU - Kingham, Victoria S.
AU - Weiser, Martin R.
AU - Balachandran, Vinod P.
AU - Drebin, Jeffrey A.
AU - Kingham, T. Peter
AU - Jarnagin, William R.
AU - D’Angelica, Michael I.
AU - Do, Richard K.G.
AU - Simpson, Amber L.
N1 - Funding Information:
This study was supported in part by NIH/NCI Cancer Center Support Grant P30 CA008748 and the Society for Memorial Sloan Kettering.
Publisher Copyright:
© 2020, Society of Surgical Oncology.
PY - 2021/4
Y1 - 2021/4
N2 - Background: Currently, there are no methods to identify patients with an increased risk of liver metastases to guide patient selection for liver-directed therapies. We tried to determine whether quantitative image features (radiomics) of the liver obtained from preoperative staging CT scans at the time of initial colon resection differ in patients that subsequently develop liver metastases, extrahepatic metastases, or demonstrate prolonged disease-free survival. Methods: Patients who underwent resection of stage II/III colon cancer from 2004 to 2012 with available preoperative CT scans were included in this single-institution, retrospective case-control study. Patients were grouped by initial recurrence patterns: liver recurrence, extrahepatic recurrence, or no evidence of disease at 5 years. Radiomic features of the liver parenchyma extracted from CT images were compared across groups. Results: The cohort consisted of 120 patients divided evenly between three recurrence groups, with an equal number of stage II and III patients in each group. After adjusting for multiple comparisons, 44 of 254 (17%) imaging features displayed different distributions across the three patient groups (p < 0.05), with the clearest distinction between those with liver recurrence and no evidence of disease. Increased heterogeneity in the liver parenchyma by radiomic analysis was protective of liver metastases. Conclusions: CT radiomics is a promising tool to identify patients at high risk of developing liver metastases and is worthy of further investigation and validation.
AB - Background: Currently, there are no methods to identify patients with an increased risk of liver metastases to guide patient selection for liver-directed therapies. We tried to determine whether quantitative image features (radiomics) of the liver obtained from preoperative staging CT scans at the time of initial colon resection differ in patients that subsequently develop liver metastases, extrahepatic metastases, or demonstrate prolonged disease-free survival. Methods: Patients who underwent resection of stage II/III colon cancer from 2004 to 2012 with available preoperative CT scans were included in this single-institution, retrospective case-control study. Patients were grouped by initial recurrence patterns: liver recurrence, extrahepatic recurrence, or no evidence of disease at 5 years. Radiomic features of the liver parenchyma extracted from CT images were compared across groups. Results: The cohort consisted of 120 patients divided evenly between three recurrence groups, with an equal number of stage II and III patients in each group. After adjusting for multiple comparisons, 44 of 254 (17%) imaging features displayed different distributions across the three patient groups (p < 0.05), with the clearest distinction between those with liver recurrence and no evidence of disease. Increased heterogeneity in the liver parenchyma by radiomic analysis was protective of liver metastases. Conclusions: CT radiomics is a promising tool to identify patients at high risk of developing liver metastases and is worthy of further investigation and validation.
UR - http://www.scopus.com/inward/record.url?scp=85091163909&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85091163909&partnerID=8YFLogxK
U2 - 10.1245/s10434-020-09134-w
DO - 10.1245/s10434-020-09134-w
M3 - Article
C2 - 32954446
AN - SCOPUS:85091163909
SN - 1068-9265
VL - 28
SP - 1982
EP - 1989
JO - Annals of Surgical Oncology
JF - Annals of Surgical Oncology
IS - 4
ER -